115 related articles for article (PubMed ID: 16892903)
1. Vaccine clinical trials--a statistical primer.
Mehrotra DV
J Biopharm Stat; 2006; 16(4):403-14. PubMed ID: 16892903
[TBL] [Abstract][Full Text] [Related]
2. Statistical considerations for noninferiority/equivalence trials in vaccine development.
Wang WW; Mehrotra DV; Chan IS; Heyse JF
J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905
[TBL] [Abstract][Full Text] [Related]
3. Multistage designs for vaccine safety studies.
Dragalin V; Fedorov V
J Biopharm Stat; 2006; 16(4):539-53. PubMed ID: 16892912
[TBL] [Abstract][Full Text] [Related]
4. Overview of vaccine field studies: types of effects and designs.
Halloran ME
J Biopharm Stat; 2006; 16(4):415-27. PubMed ID: 16892904
[TBL] [Abstract][Full Text] [Related]
5. Statistical efficiency in multiple-to-one comparison trials with optimal allocation ratio.
Zhang J; Zhang JJ
J Biopharm Stat; 2011 Jan; 21(1):125-35. PubMed ID: 21191859
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: NeuroVax, Immune Response Corp.
Darlington CL
Curr Opin Mol Ther; 2005 Dec; 7(6):598-603. PubMed ID: 16370383
[TBL] [Abstract][Full Text] [Related]
7. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
[TBL] [Abstract][Full Text] [Related]
8. Ensuring the quality, potency and safety of vaccines during preclinical development.
Lebron JA; Wolf JJ; Kaplanski CV; Ledwith BJ
Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
[TBL] [Abstract][Full Text] [Related]
9. Vaccine efficacy determination.
Broome CV
NIPH Ann; 1991 Dec; 14(2):219-21; discussion 222-4. PubMed ID: 1812435
[TBL] [Abstract][Full Text] [Related]
10. Field assays with anti-malarial vaccines: phase III protocols.
Sanchez T
Rev Inst Med Trop Sao Paulo; 1992 Apr; 34 Suppl 9():S24-7. PubMed ID: 1340629
[No Abstract] [Full Text] [Related]
11. [Sample size and number needed to treat--a statistical case study].
Møller K; Kronborg G; Dirksen A
Ugeskr Laeger; 2001 Oct; 163(44):6140-1. PubMed ID: 11715159
[TBL] [Abstract][Full Text] [Related]
12. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
13. Issues in the design and implementation of vaccine trials in less developed countries.
Deen JL; Clemens JD
Nat Rev Drug Discov; 2006 Nov; 5(11):932-40. PubMed ID: 17080029
[TBL] [Abstract][Full Text] [Related]
14. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological factors in clinical trial design.
Wassilak S
Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for the prevention of cardiovascular disease.
Ryan US; Rittershaus CW
Vascul Pharmacol; 2006 Nov; 45(5):253-7. PubMed ID: 17046334
[TBL] [Abstract][Full Text] [Related]
17. Clinical safety evaluation of combination vaccines.
Midthun K; Horne AD; Goldenthal KL
Dev Biol Stand; 1998; 95():245-9. PubMed ID: 9855438
[TBL] [Abstract][Full Text] [Related]
18. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
19. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence.
Hall W; Gartner C
Curr Opin Psychiatry; 2011 May; 24(3):191-6. PubMed ID: 21430537
[TBL] [Abstract][Full Text] [Related]
20. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials.
Jahn-Eimermacher A; du Prel JB; Schmitt HJ
Vaccine; 2007 Aug; 25(33):6237-44. PubMed ID: 17629378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
